Echothiophate Iodide Suppliers & Bulk Manufacturers

Available Forms: Ophthalmic Solution

Available Strengths: 0.125%, 0.25%

Reference Brands: Phospholine Iodide (USA)

Category: Opthalmology

Echothiophate iodide is available in Ophthalmic Solution and strengths such as 0.125%, 0.25%. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Echothiophate iodide is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Echothiophate iodide can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Echothiophate iodide, marketed under the brand name Phospholine Iodide, is an ocular antihypertensive used primarily in the treatment of open-angle glaucoma and, in certain cases, accommodative esotropia. It is a long-acting organophosphate compound that binds irreversibly to cholinesterase, leading to increased levels of acetylcholine in the eye. This mechanism enhances aqueous humor outflow through the trabecular meshwork, effectively reducing intraocular pressure.

Due to its irreversible inhibition of cholinesterase and slow hydrolysis, the effects of echothiophate can persist for a week or more, providing sustained control of intraocular pressure. The drug is administered as an ophthalmic solution, typically in concentrations of 0.125% or 0.25%, depending on the clinical indication.

While generally well-tolerated, echothiophate iodide may cause adverse effects, including ocular muscle spasms, blurred vision, headache, and, rarely, systemic cholinergic effects. Regular monitoring by an ophthalmologist is recommended to ensure optimal dosing and to minimize potential side effects. Echothiophate remains a valuable option in glaucoma management, particularly for patients requiring long-acting, sustained ocular antihypertensive therapy.